Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

This study found that tribuloside, a flavonoid from Tribulus terrestris L., enhances melanin production in human melanocytes, zebrafish, and human skin samples without causing toxicity, potentially through inhibiting PDE to increase cAMP levels and promote the melanin biosynthesis pathway.

This review highlights that various targeted cancer therapies are associated with specific ocular side-effects, emphasizing the importance of awareness among ophthalmologists for timely diagnosis and management.

This study found that N-acetylcysteine effectively prevented cyclophosphamide-induced alopecia in rats, and ImuVert plus N-acetylcysteine prevented alopecia from a cyclophosphamide-cytarabine combination.

This review discusses the development and potential therapeutic effects of nitroxide small molecule agents for age-related macular degeneration and cardiovascular disease, but reports no new clinical results.

This study found that sorafenib was active against desmoid tumors, with 25% of patients achieving a partial response and 70% maintaining stable disease.

This review discusses various Wnt pathway modulators developed between 2014 and 2020, highlighting their potential as treatments for diseases like cancer and osteoarthritis, but reports no new clinical results.

This study describes a novel cancer therapy, ONCO-NK-TRANSITION-GM1, that offers a 60-80% cure rate across multiple cancer types using existing pharmaceutical manufacturing technologies, and costs $50 per dose, presenting a more accessible alternative to current therapies.

This review discusses preclinical and clinical chemoprevention research for several cancers, noting challenges in effectiveness and toxicity, and emphasizes the need for further trials.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

CTP-543 is generally safe for treating alopecia areata.

In this study, the safety profile of the prodrug CAP7.1 was found to be similar to other topoisomerase inhibitors, with myelosuppression as the main dose-limiting toxicity.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.

This study found that prostaglandin E2 pretreatment may reduce radiotherapy-induced alopecia by enhancing hair follicle self-repair through transient G1 arrest, suggesting a potential preventive treatment.

In this study, viprostol was not effective in promoting hair growth for men with androgenetic alopecia over a 24-week period.

In this study, researchers observed a dose-dependent occurrence of persistent radiation-induced alopecia in patients with primary CNS tumors or head and neck sarcomas, noting distinctive patterns and features, and suggesting potential benefits of topical minoxidil and procedural interventions for treatment.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

The authors concluded that administering biotin may help prevent alopecia caused by reduced biotinidase activity during valproic acid therapy in rats.

This study found that topical valproate has minimal potential to cause skin irritation, suggesting it can be applied safely to human skin.

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This study identified PTEN as a key regulator in non-healing venous leg ulcers, suppressing immune responses and lymphangiogenesis, suggesting its potential as a therapeutic target for promoting VLU healing.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.

This study reviews existing literature on regenerative therapy for androgenetic alopecia, highlighting that integrating growth factors, biotin, D-pantenol, and other active ingredients using the Vittahair protocol may enhance hair follicle regeneration, increase hair density, and improve hair quality, providing a precise and evidence-based treatment alternative.

This study observed that early treatment with ritlecitinib in patients with alopecia areata, especially when severity is low, led to more favorable responses, and continued improvement was seen up to 24 months, offering guidance on treatment timing and duration.